These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 30252583

  • 1. Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study.
    Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER.
    Hum Vaccin Immunother; 2019; 15(2):503-507. PubMed ID: 30252583
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.
    Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER.
    Vaccine; 2018 Nov 12; 36(46):7017-7024. PubMed ID: 30314913
    [Abstract] [Full Text] [Related]

  • 3. Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials.
    Gilca V, Sauvageau C, Panicker G, De Serres G, Schiller J, Ouakki M, Unger ER.
    Hum Vaccin Immunother; 2019 Nov 12; 15(7-8):1980-1985. PubMed ID: 31017850
    [Abstract] [Full Text] [Related]

  • 4. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.
    Gilca V, Sauvageau C, Boulianne N, De Serres G, Crajden M, Ouakki M, Trevisan A, Dionne M.
    Hum Vaccin Immunother; 2015 Nov 12; 11(3):732-8. PubMed ID: 25714044
    [Abstract] [Full Text] [Related]

  • 5. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study.
    Toh ZQ, Russell FM, Reyburn R, Fong J, Tuivaga E, Ratu T, Nguyen CD, Devi R, Kama M, Matanitobua S, Tabrizi SN, Garland SM, Sinha R, Frazer I, Tikoduadua L, Kado J, Rafai E, Mulholland EK, Licciardi PV.
    Clin Infect Dis; 2017 Apr 01; 64(7):852-859. PubMed ID: 28034886
    [Abstract] [Full Text] [Related]

  • 6. A prospective cohort study of immunogenicity of quadrivalent human papillomavirus vaccination among Alaska Native Children, Alaska, United States.
    Bruce MG, Meites E, Bulkow L, Panicker G, Hurlburt D, Lecy D, Thompson G, Rudolph K, Unger ER, Hennessy T, Markowitz LE.
    Vaccine; 2020 Sep 29; 38(42):6585-6591. PubMed ID: 32814639
    [Abstract] [Full Text] [Related]

  • 7. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
    Patel C, Brotherton JM, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, Marshall H.
    Euro Surveill; 2018 Oct 29; 23(41):. PubMed ID: 30326995
    [Abstract] [Full Text] [Related]

  • 8. Priming effect of bivalent and quadrivalent vaccine for HPV 31/33/45/52: an exploratory analysis from two clinical trials.
    Sauvageau C, Panicker G, Unger ER, De Serres G, Schiller J, Ouakki M, Gilca V.
    Hum Vaccin Immunother; 2020 Mar 03; 16(3):590-594. PubMed ID: 31545130
    [Abstract] [Full Text] [Related]

  • 9. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.
    Zhang Z, Zhang J, Xia N, Zhao Q.
    Hum Vaccin Immunother; 2017 Oct 03; 13(10):2280-2291. PubMed ID: 28699820
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes.
    Hernández-Ávila M, Torres-Ibarra L, Stanley M, Salmerón J, Cruz-Valdez A, Muñoz N, Herrero R, Villaseñor-Ruíz IF, Lazcano-Ponce E.
    Hum Vaccin Immunother; 2016 Oct 03; 12(1):30-8. PubMed ID: 26211489
    [Abstract] [Full Text] [Related]

  • 11. The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.
    Chesson HW, Markowitz LE, Hariri S, Ekwueme DU, Saraiya M.
    Hum Vaccin Immunother; 2016 Jun 02; 12(6):1363-72. PubMed ID: 26890978
    [Abstract] [Full Text] [Related]

  • 12. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P, Tobe K, Abe M, Elbasha EH.
    BMC Infect Dis; 2021 Jan 06; 21(1):11. PubMed ID: 33407188
    [Abstract] [Full Text] [Related]

  • 13. Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose in young women aged 15-20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials.
    Baisley K, Kemp TJ, Mugo NR, Whitworth H, Onono MA, Njoroge B, Indangasi J, Bukusi EA, Prabhu PR, Mutani P, Galloway DA, Mwanzalime D, Kapiga S, Lacey CJ, Hayes RJ, Changalucha J, Pinto LA, Barnabas RV, Watson-Jones D.
    Lancet Glob Health; 2024 Mar 06; 12(3):e491-e499. PubMed ID: 38365419
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity of quadrivalent human papillomavirus vaccine among Alaska Native children aged 9-14 years at 5 years after vaccination.
    Davis BM, Blake I, Panicker G, Meites E, Thompson G, Geis J, Bruden D, Fischer M, Singleton R, Unger ER, Markowitz LE, Bruce MG.
    Vaccine; 2024 May 22; 42(14):3277-3281. PubMed ID: 38627144
    [Abstract] [Full Text] [Related]

  • 15. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
    Chow EPF, Machalek DA, Tabrizi SN, Danielewski JA, Fehler G, Bradshaw CS, Garland SM, Chen MY, Fairley CK.
    Lancet Infect Dis; 2017 Jan 22; 17(1):68-77. PubMed ID: 27282422
    [Abstract] [Full Text] [Related]

  • 16. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
    Garland SM, Cheung TH, McNeill S, Petersen LK, Romaguera J, Vazquez-Narvaez J, Bautista O, Shields C, Vuocolo S, Luxembourg A.
    Vaccine; 2015 Nov 27; 33(48):6855-64. PubMed ID: 26411885
    [Abstract] [Full Text] [Related]

  • 17. Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine.
    Guevara A, Cabello R, Woelber L, Moreira ED, Joura E, Reich O, Shields C, Ellison MC, Joshi A, Luxembourg A.
    Vaccine; 2017 Sep 05; 35(37):5050-5057. PubMed ID: 28789851
    [Abstract] [Full Text] [Related]

  • 18. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.
    Petrosky E, Bocchini JA, Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE, Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2015 Mar 27; 64(11):300-4. PubMed ID: 25811679
    [Abstract] [Full Text] [Related]

  • 19. Persistence of Immunity When Using Different Human Papillomavirus Vaccination Schedules and Booster-Dose Effects 5 Years After Primary Vaccination.
    Lazcano-Ponce E, Torres-Ibarra L, Cruz-Valdez A, Salmerón J, Barrientos-Gutiérrez T, Prado-Galbarro J, Stanley M, Muñoz N, Herrero R, Hernández-Ávila M.
    J Infect Dis; 2019 Jan 01; 219(1):41-49. PubMed ID: 30085139
    [Abstract] [Full Text] [Related]

  • 20. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF, Liu AP, Lim FS, Thollot F, Oh HM, Lee BW, Rombo L, Tan NC, Rouzier R, Friel D, De Muynck B, De Simoni S, Suryakiran P, Hezareh M, Folschweiller N, Thomas F, Struyf F.
    Hum Vaccin Immunother; 2015 Jan 01; 11(7):1689-702. PubMed ID: 26062002
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.